Anixa is a biotechnology company developing a number of programs addressing cancer and infectious disease. 

Anixa's therapeutic portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a COVID-19 therapeutics program focused on inhibiting certain viral protein function. 

Anixa’s vaccine portfolio consists of a technology focused on the immunization against a “retired” protein, α-Lactalbumin, to prevent triple negative breast cancer (TNBC), the most lethal form of breast cancer.

Anixa continually examines emerging technologies in complementary fields for further development and commercialization. 

Strong Leadership Backed by Success

Our management team has had many successes, especially in connection with starting, building and investing in technology related companies.

View Management Team

View Board of Directors